# NOTICE TO THE BAR

MULTICOUNTY LITIGATION – ALLODERM – CONCLUSION OF CENTRALIZED MANAGEMENT AND HANDLING AS MCL

In accordance with the provisions of Court Rule 4:38A and Directive #02-19, "Multicounty Litigation Guidelines and Criteria for Designation (Revised)," a September 7, 2021 Notice sought comments on the recommendation by Superior Court Judge Bruce Kaplan for conclusion of the centralized management and treatment as multicounty litigation of New Jersey state-court litigation involving the product AlloDerm. This Notice is to advise that the Supreme Court, having received no comments in objection, has acted on that recommendation and concluded the centralized management and treatment of AlloDerm cases as an MCL.

The Court's November 29, 2021 Order is published with this notice. Both also are posted on the Judiciary's Internet Website at (www.njcourts.gov) in the MCL Information Center http://www.njcourts.gov/attorneys/mcl/index.html.

Questions may be directed to Melissa A. Czartoryski, Chief, Civil Court Programs, Civil Practice Division, Administrative Office of the Courts, Hughes Justice Complex, P.O. Box 981, Trenton, New Jersey 08625-0981; telephone (609) 815-2900 ext. 54900; email address: Melissa.Czartoryski@njcourts.gov .

Glenn A. Grant, J.A.D.
Acting Administrative Director of the Courts

Dated: December 27, 2021

SUPREME COURT OF NEW JERSEY

The Supreme Court by Order dated July 12, 2011 designated all New Jersey state court litigation relating to AlloDerm Regenerative Tissue Matrix (AlloDerm) for centralized management (now multicounty litigation) and assigned that litigation to Middlesex County. The Court's initial Order has since been amended as to the designated judge, including most recently by Order dated January 25, 2021.

It is ORDERED that effective immediately, the designation of all New Jersey state court AlloDerm litigation as for centralized management and treatment as multicounty litigation is hereby concluded.

For the Court,

Chief Justice

Dated: November 29, 2021